Aclaris Therapeutics Files 8-K

Ticker: ACRS · Form: 8-K · Filed: Jul 29, 2025 · CIK: 1557746

Aclaris Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAclaris Therapeutics, INC. (ACRS)
Form Type8-K
Filed DateJul 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, disclosure

Related Tickers: ACRS

TL;DR

Aclaris Therapeutics filed an 8-K on 7/29/25 for disclosures and other events.

AI Summary

On July 29, 2025, Aclaris Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Aclaris Therapeutics is making a regulatory disclosure and reporting on other events, which could include significant business updates.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material information that would indicate a change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Aclaris Therapeutics?

The 8-K filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on July 29, 2025.

What is the principal executive office address for Aclaris Therapeutics?

The principal executive office is located at 701 Lee Road, Suite 103, Wayne, PA 19087.

What is the company's state of incorporation?

Aclaris Therapeutics, Inc. is incorporated in Delaware.

What is the IRS Employer Identification Number for Aclaris Therapeutics?

The IRS Employer Identification Number is 46-0571712.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Aclaris Therapeutics, Inc. (ACRS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing